Clinical Trials Directory

Trials / Completed

CompletedNCT02529124

Nutrient Support to Body Composition and Healthy Ageing

An Investigation of the the Effect of Nutrient Support, or Nutrient Plus Physical Activity on Musculoskeletal Health and Function in Men and Women Aged 55 to 70 Years

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
254 (actual)
Sponsor
Phil Jakeman · Academic / Other
Sex
All
Age
50 Years – 70 Years
Healthy volunteers
Accepted

Summary

The focus is healthy ageing, i.e. delaying the deterioration in health status in older adults. Loss of lean tissue (skeletal muscle) mass, a process termed sarcopenia, or bone tissue mass, a process called osteopenia, is a consequence of aging per se, modified by nutrition and lifestyle behaviour. The aim is to conduct a study of body composition, physical activity, muscle function and ability to undertake activities of daily living in older Irish men and women and to investigate the effect of a six month period of nutrient support, or nutrient plus physical activity on lean tissue mass and function and bone mass in men and women aged 50 to 70 years.

Detailed description

Study Design: The study is a convenience population study and 6-month randomised control trial (RCT) of men and women age 55 to 70 years. The study groups (n=60 per group) for the RCT are: 1. CON - a control group receiving a placebo nutrient support (per kg of body mass: 0.25g maltodextrin; energy \~ 160 kcal per day) 2. PRO - a nutrient group receiving a nutrient support (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy \~ 160 kcal per day) 3. PRO+PA - a nutrient group receiving a nutrient support (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy \~ 160 kcal per day) and engaging in a prescribed physical activity (PA). Subject recruitment: Men and women, age 50 to 70 years, will be recruited through the UL Body Composition Study, by email advertisement, GP-exercise referral scheme, feature article(s) in the local media and word of mouth. Requirement of the participants. On entry each subject will undertake a preliminary assessment as follows: i. medical history and examination by a qualified medical doctor ; ii. provide a blood and urine sample to be evaluated by a qualified medical doctor; iii. food intake evaluated by a qualified dietician; iv. whole body and segmental body composition analysis (DXA); v. habitual physical activity level (PAL) vi. measurement of muscle function and performance in simulated activities of daily living. One month following the preliminary assessment subjects will be invited to participate in a 6 month intervention programme of nutrient or nutrient plus physical activity. Consenting subjects will be randomly assigned to one of the three study groups stated above. Upon completion (6 months), subjects will be re-assessed as follows; i. provide a blood and urine sample; ii. whole body and segmental body composition analysis (DXA); iii. measurement of muscle function and performance in simulated activities of daily living.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTCONTROLMaltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
DIETARY_SUPPLEMENTPROTEINThe milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
BEHAVIORALPHYSICAL ACTIVITYA structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.

Timeline

Start date
2012-01-01
Primary completion
2016-05-01
Completion
2016-05-01
First posted
2015-08-19
Last updated
2016-06-27

Source: ClinicalTrials.gov record NCT02529124. Inclusion in this directory is not an endorsement.